Remove 2003 Remove DNA Remove Therapies Remove Treatment
article thumbnail

Why genomic healthcare data matters in the development of new therapies 

Drug Discovery World

Genomic healthcare data is critical to identify disease risk, ancestry, traits and response to medicines and aids in the development of new targeted therapies – precision medicines. In April 2003, after its launch in October 1990, the project was completed, generating the first sequence of the human genome. The origins .

Therapies 246
article thumbnail

Where is the drug discovery expertise happening in the UK?

Drug Discovery World

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. The university aims to identify treatments for life-threatening anti-microbial diseases and metabolic disorders.

Drugs 189
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

China’s National Medical Products Administration approves Benlysta (belimumab) for adult patients with active lupus nephritis

The Pharma Data

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that China’s National Medical Products Administration (NMPA) has approved Benlysta (belimumab) for the treatment of adult patients with active lupus nephritis (LN) who are receiving standard of care. 8) in combination with standard of care. About lupus.

article thumbnail

New understanding of the TMEJ pathway in cancer

Drug Target Review

Throughout the course of our lives, natural and environmental factors can break DNA. Breaks in both DNA strands are a particularly dangerous threat to genome stability. At a DNA double-strand break (DSB), potentially lost sequence information cannot be recovered from the same DNA molecule.

DNA 59
article thumbnail

Antibody-drug conjugates payloads: then, now and next

Drug Target Review

Antibody-drug conjugates (ADCs) have been a groundbreaking approach to cancer treatment with their ability to deliver cytotoxic drugs directly to diseased cells while sparing healthy tissues. 2 In response, DNA-damaging agents that could target the entire cell cycle received renewed attention as ADC payloads.

article thumbnail

Welcome to Asimov Press

Codon

Recombinant DNA technologies were invented in the 1970s. A first draft of the human genome was completed in 2003. At least six CAR-T cancer therapies have now garnered F.D.A. Laundry may not be as immediately headline-grabbing as new cancer therapies, but it provides a concrete and ingenious solution to a demonstrable need.